MA35049B1 - Triazolopyridines - Google Patents

Triazolopyridines

Info

Publication number
MA35049B1
MA35049B1 MA36344A MA36344A MA35049B1 MA 35049 B1 MA35049 B1 MA 35049B1 MA 36344 A MA36344 A MA 36344A MA 36344 A MA36344 A MA 36344A MA 35049 B1 MA35049 B1 MA 35049B1
Authority
MA
Morocco
Prior art keywords
triazolopyridines
general formula
relates
present
triazolopyridine compounds
Prior art date
Application number
MA36344A
Other languages
English (en)
Inventor
Volker Schulze
Dirk Kosemund
Antje Margret Wengner
Gerhard Siemeister
Detlef Stöckigt
Philip Lienau
Hartmut Schirok
Hans Briem
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA35049B1 publication Critical patent/MA35049B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés triazolopyridine de formule générale (I) : dans laquelle les R
MA36344A 2011-04-21 2012-04-16 Triazolopyridines MA35049B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27
PCT/EP2012/056914 WO2012143329A1 (fr) 2011-04-21 2012-04-16 Triazolopyridines

Publications (1)

Publication Number Publication Date
MA35049B1 true MA35049B1 (fr) 2014-04-03

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36344A MA35049B1 (fr) 2011-04-21 2012-04-16 Triazolopyridines

Country Status (39)

Country Link
US (1) US20140120087A1 (fr)
EP (1) EP2699575B1 (fr)
JP (1) JP5989091B2 (fr)
KR (1) KR20140025470A (fr)
CN (1) CN103608350B (fr)
AP (1) AP3491A (fr)
AR (1) AR086191A1 (fr)
AU (1) AU2012244859B2 (fr)
CA (1) CA2833657A1 (fr)
CL (1) CL2013003044A1 (fr)
CO (1) CO6801751A2 (fr)
CR (1) CR20130539A (fr)
CY (1) CY1116439T1 (fr)
DK (1) DK2699575T3 (fr)
DO (1) DOP2013000244A (fr)
EA (1) EA023766B1 (fr)
EC (1) ECSP13013011A (fr)
ES (1) ES2539265T3 (fr)
GT (1) GT201300254A (fr)
HK (1) HK1190398A1 (fr)
HR (1) HRP20150517T1 (fr)
HU (1) HUE025496T2 (fr)
IL (1) IL228704A0 (fr)
JO (1) JO3040B1 (fr)
MA (1) MA35049B1 (fr)
ME (1) ME02143B (fr)
MX (1) MX348783B (fr)
MY (1) MY164939A (fr)
PE (1) PE20141351A1 (fr)
PL (1) PL2699575T3 (fr)
PT (1) PT2699575E (fr)
RS (1) RS54044B1 (fr)
SA (1) SA112330466B1 (fr)
SG (1) SG194003A1 (fr)
SI (1) SI2699575T1 (fr)
TW (1) TWI558703B (fr)
UY (1) UY34034A (fr)
WO (1) WO2012143329A1 (fr)
ZA (1) ZA201308707B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2013103724A1 (fr) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Dérivés d'acide 2-(tert-butoxy)-2-(7-méthylquinoléin-6-yl)acétique pour traiter le sida
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
EP2825540B1 (fr) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Imidazolpyridazines substituées
SG11201408419QA (en) 2012-07-10 2015-01-29 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
WO2014020041A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
ES2626989T3 (es) * 2013-06-07 2017-07-26 Bayer Pharma Aktiengesellschaft Triazolopiridinas sustituidas
CA2914521A1 (fr) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Triazolopyridines substituees ayant une activite d'inhibiteur mps-1
EP3008061A1 (fr) * 2013-06-10 2016-04-20 Bayer Pharma Aktiengesellschaft Nouveaux composés destinés au traitement du cancer
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
CN105377848A (zh) * 2013-06-11 2016-03-02 拜耳制药股份公司 取代的三唑并吡啶的前体药物衍生物
EP2860177A3 (fr) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthèse d'arènes fonctionnalisés
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
EP3575301A4 (fr) * 2017-03-16 2020-08-05 Jiangsu Hengrui Medicine Co., Ltd. Dérivé d'hétéroaryl[4,3-c]pyrimidine-5-amine, son procédé de préparation et ses utilisations médicales
AU2020257301A1 (en) 2019-04-18 2021-11-11 The Johns Hopkins University Substituted 2-amino-pyrazolyl-(1,2,4)triazolo(1,5a) pyridine derivatives and use thereof
CA3145864A1 (fr) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de tyrosine kinase non recepteur 1 (tnk1) et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ES2315909T3 (es) 2004-08-17 2009-04-01 GALDERMA RESEARCH & DEVELOPMENT Nuevos compuestos bioaromaticos que son activadores de los receptores del tipo ppar y su utilizacion en composiciones cosmeticas y farmaceuticas.
CN103641829A (zh) * 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
JP2010533680A (ja) 2007-07-18 2010-10-28 ノバルティス アーゲー 二環ヘテロアリール化合物およびそれらのキナーゼ阻害剤としての使用
AU2008290330A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of TTK/Mps1 for the treatment of proliferative disorders
EA201070328A1 (ru) * 2007-08-31 2010-08-30 Мерк Сероно С.А. Соединения триазолопиридина и их применение в качестве ингибиторов ask
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR20100086492A (ko) * 2007-11-27 2010-07-30 셀좀 리미티드 Ｐｉ3ｋ 억제제로서의 아미노 트리아졸
JP2012517971A (ja) 2009-02-13 2012-08-09 フォーヴィア・ファーマシューティカルズ キナーゼ阻害薬としての［１，２，４］トリアゾロ［１，５−ａ］ピリジン類
JP6168773B2 (ja) 2009-04-29 2017-07-26 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾキノキサリン
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
MX2013012289A (es) 2013-11-21
TW201245194A (en) 2012-11-16
EP2699575B1 (fr) 2015-03-25
KR20140025470A (ko) 2014-03-04
EP2699575A1 (fr) 2014-02-26
HK1190398A1 (zh) 2014-07-04
SA112330466B1 (ar) 2015-09-28
DOP2013000244A (es) 2014-03-16
EA201301181A1 (ru) 2014-08-29
SI2699575T1 (sl) 2015-10-30
US20140120087A1 (en) 2014-05-01
CR20130539A (es) 2013-12-04
ME02143B (me) 2015-10-20
AP3491A (en) 2015-12-31
PT2699575E (pt) 2015-07-29
JO3040B1 (ar) 2016-09-05
CL2013003044A1 (es) 2014-05-02
PL2699575T3 (pl) 2015-08-31
UY34034A (es) 2012-11-30
HUE025496T2 (en) 2016-04-28
AP2013007182A0 (en) 2013-10-31
GT201300254A (es) 2015-09-01
RS54044B1 (en) 2015-10-30
CN103608350B (zh) 2015-11-25
MX348783B (es) 2017-06-28
ECSP13013011A (es) 2013-12-31
WO2012143329A1 (fr) 2012-10-26
EA023766B1 (ru) 2016-07-29
CY1116439T1 (el) 2017-02-08
ZA201308707B (en) 2016-07-27
CN103608350A (zh) 2014-02-26
DK2699575T3 (da) 2015-06-22
ES2539265T3 (es) 2015-06-29
CA2833657A1 (fr) 2012-10-26
IL228704A0 (en) 2013-12-31
NZ616456A (en) 2015-09-25
JP2014511887A (ja) 2014-05-19
SG194003A1 (en) 2013-11-29
AU2012244859A1 (en) 2013-10-31
AR086191A1 (es) 2013-11-27
TWI558703B (zh) 2016-11-21
MY164939A (en) 2018-02-15
CO6801751A2 (es) 2013-11-29
JP5989091B2 (ja) 2016-09-07
PE20141351A1 (es) 2014-11-01
AU2012244859B2 (en) 2017-06-08
HRP20150517T1 (hr) 2015-06-19

Similar Documents

Publication Publication Date Title
MA35049B1 (fr) Triazolopyridines
MA37940A2 (fr) Nouveaux dérivés bicycliques
MA35664B1 (fr) Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA35086B1 (fr) Compose de triazolopyridine
CR20140042A (es) Indazoles
MA35357B1 (fr) Composes de type anilines
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
CR20130129A (es) Anàlogos de buprenorfina
MA35926B1 (fr) Pyrrolidine-2-carboxamides substitués
IN2014MN02496A (fr)
CR20120295A (es) Triazolopiridinas
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
AU2012213775A8 (en) 7-azaindole derivatives
CR20120637A (es) Triazolopiridinas sustituidas
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
EA202190619A1 (ru) Противовирусные соединения
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
CR20130045A (es) Compuestos terapéuticos
CR20130369A (es) Novedosos derivados heterocíclicos
MA38645A1 (fr) Nouveaux inhibiteurs de cyp17/antiandrogènes
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA37943B1 (fr) 2-oxo-2,3-dihydro-indoles destinés au traitement de troubles du snc
MA37686B1 (fr) Composés phénoxyéthyl pipéridine